



Onko-Sure[®]

The Power of Knowing

According to the National Cancer Society, there are 1.1 million people with colorectal cancer (CRC) in the United States and over 10 million people who are CRC survivors. For CRC survivors, effective monitoring for disease recurrence is perhaps the most important part of an effective post-surgery treatment plan.

Onko-Sure[®] is the first new cancer test to be cleared in the USA for the monitoring of CRC in over 25 years. In early CRC stages (Dukes stages A & B), between 68% and 97% of the biopsy positive patients have negative CEA values and are unable to be monitored with CEA.

Onko-Sure[®] is US FDA cleared for colorectal cancer monitoring. It is used to check for cancer recurrence or disease status during cancer treatment.




Figure 1. 50% or more CRC patients have low CEA values (<30). As demonstrated in the graph above, Onko-Sure[®] (blue line) showed increased positive concordance, i.e. ability to monitor patients with low CEA values.

Onko-Sure[®]

The Power of Knowing



Onko-Sure[®] Advantages

- Simple, non-invasive blood test
- US FDA cleared for colorectal cancer monitoring - used to check for cancer recurrence or disease status during cancer treatment
- Standard Sandwich ELISA format
 - *automation-ready*
- Onko-Sure[®] detects a biomarker which:
 - *is abundant in serum*
 - *floats-freely in blood (unlike CEA)*
 - *has levels that rise dramatically with cancer progression (up to 38 times greater than in normal patients)*
- Onko-Sure[®] adds clinical value for monitoring CRC patients with low CEA values

Ordering Information

Part No.	Description	Qty.
DR2102	Onko-Sure [®] DR-70 ELISA Cancer Test	96 wells



email : sales@radiant-pharma.com



www.onko-sure.com